The “Great Debate” at Melanoma Bridge 2021, December 2nd–4th, 2021

Paolo A. Ascierto; Allison Betof Warner; Christian Blank; Corrado Caracò; Sandra Demaria; Jeffrey E. Gershenwald; Nikhil I. Khushalani; Georgina V. Long; Jason J. Luke; Janice M. Mehnert; Caroline Robert; Piotr Rutkowski; Hussein A. Tawbi; Iman Osman; Igor Puzanov

doi:10.1186/s12967-022-03406-7

The “Great Debate” at Melanoma Bridge 2021, December 2nd–4th, 2021

Paolo A. Ascierto, Allison Betof Warner, Christian Blank, Corrado Caracò, Sandra Demaria, Jeffrey E. Gershenwald, Nikhil I. Khushalani, Georgina V. Long, Jason J. Luke, Janice M. Mehnert, Caroline Robert, Piotr Rutkowski, Hussein A. Tawbi, Iman Osman, Igor Puzanov

Research output: Contribution to journal › Article › peer-review

1 Citation (Scopus)

Abstract

The Great Debate session at the 2021 Melanoma Bridge virtual congress (December 2–4) featured counterpoint views from experts on seven important issues in melanoma. The debates considered the use of adoptive cell therapy versus use of bispecific antibodies, mitogen-activated protein kinase (MAPK) inhibitors versus immunotherapy in the adjuvant setting, whether the use of corticosteroids for the management of side effects have an impact on outcomes, the choice of programmed death (PD)-1 combination therapy with cytotoxic T-lymphocyte-associated antigen (CTLA)-4 or lymphocyte-activation gene (LAG)-3, whether radiation is needed for brain metastases, when lymphadenectomy should be integrated into the treatment plan and then the last debate, telemedicine versus face-to-face. As with previous Bridge congresses, the debates were assigned by meeting Chairs and positions taken by experts during the debates may not have necessarily reflected their respective personal view. Audiences voted both before and after each debate.

Original language	English
Article number	200
Journal	Journal of Translational Medicine
Volume	20
Issue number	1
DOIs	https://doi.org/10.1186/s12967-022-03406-7
Publication status	Published - 1 Dec 2022

Keywords

Adjuvant
Anti-CTLA-4
Anti-PD-1
BRAF inhibitor
Immunotherapy
Lymphadenectomy
MEK inhibitor
Melanoma; staging
Neoadjuvant
Surgery
Targeted therapy

Access to Document

10.1186/s12967-022-03406-7

Cite this

Ascierto, P. A., Warner, A. B., Blank, C., Caracò, C., Demaria, S., Gershenwald, J. E., Khushalani, N. I., Long, G. V., Luke, J. J., Mehnert, J. M., Robert, C., Rutkowski, P., Tawbi, H. A., Osman, I., & Puzanov, I. (2022). The “Great Debate” at Melanoma Bridge 2021, December 2nd–4th, 2021. Journal of Translational Medicine, 20(1), Article 200. https://doi.org/10.1186/s12967-022-03406-7

@article{51895b83c578434c868349b50d2fc4ad,

title = "The “Great Debate” at Melanoma Bridge 2021, December 2nd–4th, 2021",

abstract = "The Great Debate session at the 2021 Melanoma Bridge virtual congress (December 2–4) featured counterpoint views from experts on seven important issues in melanoma. The debates considered the use of adoptive cell therapy versus use of bispecific antibodies, mitogen-activated protein kinase (MAPK) inhibitors versus immunotherapy in the adjuvant setting, whether the use of corticosteroids for the management of side effects have an impact on outcomes, the choice of programmed death (PD)-1 combination therapy with cytotoxic T-lymphocyte-associated antigen (CTLA)-4 or lymphocyte-activation gene (LAG)-3, whether radiation is needed for brain metastases, when lymphadenectomy should be integrated into the treatment plan and then the last debate, telemedicine versus face-to-face. As with previous Bridge congresses, the debates were assigned by meeting Chairs and positions taken by experts during the debates may not have necessarily reflected their respective personal view. Audiences voted both before and after each debate.",

keywords = "Adjuvant, Anti-CTLA-4, Anti-PD-1, BRAF inhibitor, Immunotherapy, Lymphadenectomy, MEK inhibitor, Melanoma; staging, Neoadjuvant, Surgery, Targeted therapy",

author = "Ascierto, {Paolo A.} and Warner, {Allison Betof} and Christian Blank and Corrado Carac{\`o} and Sandra Demaria and Gershenwald, {Jeffrey E.} and Khushalani, {Nikhil I.} and Long, {Georgina V.} and Luke, {Jason J.} and Mehnert, {Janice M.} and Caroline Robert and Piotr Rutkowski and Tawbi, {Hussein A.} and Iman Osman and Igor Puzanov",

note = "Publisher Copyright: {\textcopyright} 2022, The Author(s).",

year = "2022",

month = dec,

day = "1",

doi = "10.1186/s12967-022-03406-7",

language = "English",

volume = "20",

journal = "Journal of Translational Medicine",

issn = "1479-5876",

number = "1",

}

TY - JOUR

T1 - The “Great Debate” at Melanoma Bridge 2021, December 2nd–4th, 2021

AU - Ascierto, Paolo A.

AU - Warner, Allison Betof

AU - Blank, Christian

AU - Caracò, Corrado

AU - Demaria, Sandra

AU - Gershenwald, Jeffrey E.

AU - Khushalani, Nikhil I.

AU - Long, Georgina V.

AU - Luke, Jason J.

AU - Mehnert, Janice M.

AU - Robert, Caroline

AU - Rutkowski, Piotr

AU - Tawbi, Hussein A.

AU - Osman, Iman

AU - Puzanov, Igor

PY - 2022/12/1

Y1 - 2022/12/1

N2 - The Great Debate session at the 2021 Melanoma Bridge virtual congress (December 2–4) featured counterpoint views from experts on seven important issues in melanoma. The debates considered the use of adoptive cell therapy versus use of bispecific antibodies, mitogen-activated protein kinase (MAPK) inhibitors versus immunotherapy in the adjuvant setting, whether the use of corticosteroids for the management of side effects have an impact on outcomes, the choice of programmed death (PD)-1 combination therapy with cytotoxic T-lymphocyte-associated antigen (CTLA)-4 or lymphocyte-activation gene (LAG)-3, whether radiation is needed for brain metastases, when lymphadenectomy should be integrated into the treatment plan and then the last debate, telemedicine versus face-to-face. As with previous Bridge congresses, the debates were assigned by meeting Chairs and positions taken by experts during the debates may not have necessarily reflected their respective personal view. Audiences voted both before and after each debate.

AB - The Great Debate session at the 2021 Melanoma Bridge virtual congress (December 2–4) featured counterpoint views from experts on seven important issues in melanoma. The debates considered the use of adoptive cell therapy versus use of bispecific antibodies, mitogen-activated protein kinase (MAPK) inhibitors versus immunotherapy in the adjuvant setting, whether the use of corticosteroids for the management of side effects have an impact on outcomes, the choice of programmed death (PD)-1 combination therapy with cytotoxic T-lymphocyte-associated antigen (CTLA)-4 or lymphocyte-activation gene (LAG)-3, whether radiation is needed for brain metastases, when lymphadenectomy should be integrated into the treatment plan and then the last debate, telemedicine versus face-to-face. As with previous Bridge congresses, the debates were assigned by meeting Chairs and positions taken by experts during the debates may not have necessarily reflected their respective personal view. Audiences voted both before and after each debate.

KW - Adjuvant

KW - Anti-CTLA-4

KW - Anti-PD-1

KW - BRAF inhibitor

KW - Immunotherapy

KW - Lymphadenectomy

KW - MEK inhibitor

KW - Melanoma; staging

KW - Neoadjuvant

KW - Surgery

KW - Targeted therapy

UR - http://www.scopus.com/inward/record.url?scp=85129889088&partnerID=8YFLogxK

U2 - 10.1186/s12967-022-03406-7

DO - 10.1186/s12967-022-03406-7

M3 - Article

C2 - 35538491

AN - SCOPUS:85129889088

SN - 1479-5876

VL - 20

JO - Journal of Translational Medicine

JF - Journal of Translational Medicine

IS - 1

M1 - 200

ER -

The “Great Debate” at Melanoma Bridge 2021, December 2nd–4th, 2021

Abstract

Keywords

Access to Document

Other files and links

Cite this